Küleon Bioscience
Allen Barbieri has a extensive work experience in various industries. Currently, they are the Chairman/CEO of Kuleon Bioscience, a drug discovery company. Allen has led the development of new patented drugs for the treatment of schizophrenia, obesity, addiction, and chronic depression. Previously, they served as Vice Chairman and Board Member at Biomerica, Inc., where they led board meetings and managed strategic projects and partnerships. Allen was also a Board Member at CareTrust REIT, a healthcare real estate investment trust, where they chaired the Corporate Governance and Nominating Committee and participated in the Audit and Compensation Committees. Prior to that, they served as Chairman/CEO at Biosynthetic Technologies, a technology company that developed and commercialized bio-based industrial oils. Allen successfully raised $60 million in VC funding, filed numerous patents, and oversaw the sale of the company to a large international chemicals PE fund. Additionally, they were the CEO of Lancer Orthodontics, where they managed sales, manufacturing, distributor relationships, and strategy. Allen also held leadership positions at BUY.COM, Pacific National Bank, Alta Residential Mortgage Trust - REIT, Capital Bancorp, and First Federal Bank, where they demonstrated proficiency in finance, operations management, and strategic planning.
Allen Barbieri has an MBA degree in Finance & International Economics from the MIT Sloan School of Management. Prior to that, they completed their undergraduate studies at Brigham Young University, earning a B/S degree in Business Finance.
This person is not in any teams
This person is not in any offices
Küleon Bioscience
Küleon is a drug discovery company focused on developing novel serotonergic drugs for the targeted treatment of various neuropsychiatric diseases and disorders. We’ve created a proprietary portfolio of serotonin receptor ligands designed to target neurocircuit abnormalities in the brain that are responsible for difficult-to-treat disorders such as schizophrenia and depression. We have successfully identified several preclinical leads that have significantly improved agonism characteristics such as low-to-no hallucinogenic or cardiotoxic liability, as well as modified PK/PD profiles when compared to other known atypical antipsychotics and serotonergic drugs. Serotonergic drugs have the potential to address multiple indications affecting large population groups that make up extremely sizable markets. This is because many of the current SSRIs and non-selective serotonin receptor agonists were not designed with an eye towards functional selectivity. Our novel compounds are designed for functional selectivity via biased signalling mechanisms, potentially enhancing their therapeutic effect and reducing unwanted side effects. Our proprietary molecular scaffolds and compounds are novel and patentable, providing us with a tremendous strategic foothold in the market as companies continue to explore novel mechanisms of action for targeting neuropsychiatric diseases and disorders. We are collaborating with some of the world’s leading academic researchers and key opinion leaders in the serotonergic and atypical antipsychotic drug development space. Please reach out if you would like learn more about the work we are doing with our collaborators!